Aptose Biosciences Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Stock-based Compensation (Tables)

Note 11 - Stock-based Compensation (Tables)

9 Months Ended

Sep. 30, 2022

Notes Tables

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

						Nine months ended September 30, 2022
		Options (in thousands)				Weighted average exercise price				Weighted average remaining contractual life (years)

Outstanding, beginning of period			15,112			$	4.61
Granted			6,295				1.19
Exercised			(14	)			1.08
Forfeited			(2,325	)			3.16
Outstanding, end of the period			19,068				3.60				6.30
Exercisable, end of the period			10,564				4.53				4.50
Vested and expected to vest, end of period			17,790			$	3.68				6.14

						Nine months ended September 30, 2021
		Options (in thousands)				Weighted average exercise price				Weighted average remaining contractual life (years)

Outstanding, beginning of period			11,942			$	4.97
Granted			4,199				4.04
Exercised			(67	)			2.39
Forfeited			(1,205	)			5.47
Outstanding, end of the period			14,869				4.68				6.8
Exercisable, end of the period			8,092				4.55				5.5
Vested and expected to vest, end of period			13,851			$	4.67				6.7

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

		Nine months ended September 30, 2022				Nine months ended September 30, 2021

Risk-free interest rate			2.17	%			0.52	%
Expected dividend yield			-				-
Expected volatility			82.7	%			81.8	%
Expected life of options		5 years				5 years
Grant date fair value		$	0.79			$	2.59

Schedule of Share-based Payment Award, Options, Grants in Period [Table Text Block]

		Nine months ended September 30, 2022				Nine months ended September 30, 2021
		Number of options (in thousands)				Number of options (in thousands)
3-year vesting (50%-25%-25%)			5,220				430
4-year vesting (50%-16 2/3%-16 2/3%-16 2/3%)			475				2,969
Earlier of performance criteria or 4 years			600				800
Total stock options granted in the period			6,295				4,199

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

		Three months ended September 30,								Nine months ended September 30,
		2022				2021				2022				2021

Research and development		$	440			$	609			$	1,923			$	2,985
General and administrative			613				1,219				2,423				7,650
		$	1,053			$	1,828			$	4,346			$	10,635